Updated November 11, 2025
Key takeaways
- New contract: United States Antimony Corporation (NYSE American: UAMY) executed a five‑year supply agreement valued at up to $106.7 million to deliver antimony trioxide to a U.S. industrial fabric manufacturer; the pact includes an option to extend up to five additional years. The customer was not named, and USAC says its material met the buyer’s technical specs in testing earlier this year. [1]
- Price action: UAMY closed at $8.07 on Tuesday, up ~5% on the day. [2]
- Macro backdrop: China suspended its ban on exports of gallium, germanium and antimony to the U.S. through Nov. 27, 2026, but licensing requirements remain—keeping some supply risk in the system. [3]
- Earnings on deck: USAC will report Q3 2025 results Wednesday, Nov. 12 at 4:15 p.m. ET via webcast and call. Street previews vary, with revenue estimates near $12.9 million and EPS between $0.01 and $0.02. [4]
UAMY stock news today (Nov. 11, 2025)
US Antimony signs $106.7M, five‑year supply deal. Before the bell, USAC announced a definitive five‑year agreement to supply antimony trioxide—used primarily as a flame‑retardant synergist for industrial fabrics—to a U.S.‑based manufacturer. The company notes the customer completed materials testing earlier in 2025, and the contract includes a five‑year renewal option beyond the initial term. Headline value is “up to $106.7 million” across the first five years. [5]
Shares finished higher. On the news, UAMY settled at $8.07 (+~5%). While the close reflects upbeat sentiment around the fresh order book, traders will look for clarity on delivery timing, ramp cadence and any margin commentary on Wednesday’s call. [6]
Why this contract matters
The announcement is material for two reasons:
- Visibility and diversification. USAC’s book now spans civilian industrial demand (antimony trioxide for flame‑retardant applications) in addition to government demand for antimony metal. In September, the company disclosed a five‑year, sole‑source contract worth up to $245 million with the U.S. Defense Logistics Agency (DLA) to supply antimony ingots for the National Defense Stockpile. If both agreements are fulfilled at their maximum values, aggregate contracted opportunities exceed $351 million—a useful (if not guaranteed) directional indicator for potential revenue coverage over the next several years. [7]
- Domestic supply strategy. The buyer’s rationale, per the announcement, is to anchor critical inputs domesticallyand reduce exposure to international disruptions and price shocks. That theme is consistent with U.S. policy and private‑sector moves to localize critical‑mineral supply chains. [8]
Macro backdrop: China’s export stance shifts—but risk remains
The geopolitical overhang on antimony eased slightly after Beijing suspended its ban on shipments of gallium, germanium and antimony to the U.S., effective Nov. 9, 2025, as part of a broader de‑escalation package. Crucially, export licensing still applies, meaning administrative friction can continue to bottleneck flows and inject volatility into pricing. The suspension currently runs through Nov. 27, 2026. [9]
Market participants told Fastmarkets today that uncertainty still lingers: inspections, sporadic clearances and opaque policy signals keep buyers cautious even with the headline suspension. For domestic processors like USAC, that backdrop reinforces the value of home‑grown procurement and long‑term offtakes that reduce reliance on Chinese supply. [10]
Earnings preview: what to watch on Wednesday
US Antimony will release Q3 2025 financial and operating results on Wednesday, Nov. 12 at 4:15 p.m. ET, followed by a 60‑minute webcast and Q&A. The company has posted dial‑in details and a replay plan on its investor site and press‑release feed. [11]
- Consensus snapshot: Previews vary across outlets: several trackers point to revenue around $12.86–$12.96 million and EPS between $0.01 and $0.02. Expect management’s guidance and color on the newly announced contract to drive the post‑call narrative. [12]
5 things investors should listen for:
- Revenue recognition timing for the new five‑year antimony trioxide agreement (start date, quarterly cadence, and any minimum volumes). [13]
- Margin profile of antimony trioxide relative to antimony metal and other product lines under current pricing. (Context: licensing remains in China, which can influence feedstock availability and premiums.) [14]
- DLA contract updates (delivery orders to date, logistics, and inventory readiness). [15]
- Feedstock strategy and procurement mix across the U.S., Mexico and Canada given lingering export‑license uncertainty. [16]
- Balance‑sheet capacity (working capital and capex needs) to support simultaneous government and commercial ramps.
Sector pulse: demand signals and competitive context
Antimony’s demand profile extends well beyond flame retardants. In an S&P Global Commodity Insights interview published today, Larvotto Resources’ MD highlighted growing antimony use in solar‑panel glass and optics, while also noting the U.S. supply gap that has drawn increased government and investor attention in 2025. The same piece references Larvotto’s Oct. 27 rejection of a takeover proposal from US Antimony, underscoring how strategic assets in the metal are being contested amid tight global supply. [17]
UAMY price and valuation snapshot (today)
- Close: $8.07 (Tuesday, Nov. 11, 2025), roughly +5% on the day. [18]
- Catalysts next 48 hours: Q3 print and guidance; any commentary on the $106.7M contract ramp and interplay with the $245M DLA award. [19]
Bottom line
For today, Nov. 11, 2025, the story around UAMY is straightforward: a new $106.7M five‑year commercial contractputs more visibility in the pipeline, the share price responded positively, and macro risk from China’s export regime is reduced but not removed. With earnings tomorrow, investors now shift from headlines to execution—seeking specifics on delivery timing, margin durability, and how management will sequence government and commercial demand through 2026. [20]
Disclosure: This article is for informational/educational purposes only and is not investment advice. Always do your own research.
References
1. www.accessnewswire.com, 2. www.marketscreener.com, 3. www.reuters.com, 4. www.usantimony.com, 5. www.accessnewswire.com, 6. www.marketscreener.com, 7. www.reuters.com, 8. www.accessnewswire.com, 9. www.reuters.com, 10. www.fastmarkets.com, 11. www.usantimony.com, 12. www.gurufocus.com, 13. www.accessnewswire.com, 14. www.reuters.com, 15. www.reuters.com, 16. www.fastmarkets.com, 17. www.spglobal.com, 18. www.marketscreener.com, 19. www.accessnewswire.com, 20. www.accessnewswire.com
